DRG Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and the total and diagnosed prevalence of RA for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, France, Germany, Italy, Spain, United Kingdom, and Japan and 10 years for the other countries covered in this report.

DRG Epidemiology’s RA forecast will answer the following questions:

  • In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of RA?
  • Of all people with RA, how many in each country under study have been formally diagnosed?
  • Of all people diagnosed with RA, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of RA over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, DRG Epidemiology forecasts nine RA patient populations, as follows:

  • Prevalent cases.
  • Diagnosed prevalent cases.
  • Undiagnosed prevalent cases.
  • Diagnosed drug-treated prevalent cases.
  • Diagnosed non-drug-treated prevalent cases.
  • Incident cases.
  • Diagnosed mild (2.61-3.2) prevalent cases.
  • Diagnosed moderate (3.21-5.1) prevalent cases.
  • Diagnosed severe (5.1+) prevalent cases.

Note: Coverage may vary by country.

Table of contents

  • Rheumatoid Arthritis - Epidemiology - Emerging Markets

Author(s): Sunali D. Goonesekera, SM

Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group.

Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a B.A. in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.


Related Reports

Rheumatoid Arthritis - Landscape & Forecast - Disease Landscape & Forecast

View Details

Rheumatoid Arthritis - Current Treatment - Rheumatoid Arthritis | Treatment Algorithms: Claims Data Analysis | US | Dashboard

MARKET OUTLOOK Rheumatoid arthritis (RA) is characterized by chronic and progressive joint inflammation that commonly leads to permanent, debilitating tissue damage and cartilage and bone d...

View Details

Rheumatoid Arthritis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

MARKET OUTLOOKRheumatoid arthritis (RA) is characterized by chronic and progressive joint inflammation that commonly leads to permanent, debilitating tissue damage and cartilage and bone des...

View Details

Rheumatoid Arthritis - Unmet Need - Detailed, Expanded Analysis: TNF-alpha Refractory Rheumatoid Arthritis (US & EU )

Rheumatoid arthritis (RA) patients refractory to one or more tumor necrosis factor-alpha (TNF-α) inhibitor...

View Details